With positive PhIII data in hot flashes, Bayer is a step closer to challenging Astellas’ Veozah
19 Mar 2024
Phase 3Clinical Result
Bayer’s non-hormonal drug candidate for hot flashes in postmenopausal women has succeeded in the last of a trio of registrational trials, setting the stage for regulatory filings.
The Phase III OASIS 3 trial set elinzanetant against placebo in postmenopausal women with vasomotor symptoms or hot flashes. The drug met the primary endpoint, achieving a significant reduction in the frequency of moderate to severe hot flashes at 12 weeks versus placebo, Bayer said in a Tuesday release.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.